Literature DB >> 1263110

Effects of halothane anesthesia on the biodisposition of ketamine in rats.

P F White, M P Marietta, C R Pudwill, W L Way, A J Trevor.   

Abstract

Ketamine, a highly lipophilic drug, was rapidly distributed into highly vascular organs and subsequently redistributed to less well perfused tissues, with concurrent hepatic metabolism and urinary and biliary excretion, after both i. m. and i. v. administration in the rat. Halothane, a potent cardiovascular depressant, was found to prolong the plasma and brain half-life of ketamine (50 mg/kg i.m.) and also increased the duration of ketamine-induced ataxia when the two drugs were administered concomitantly. Halothane anesthesia (0.8% halothane in oxygen) produced a decrease in the rate of uptake and delayed distribution and redistribution of ketamine (50 mg/kg i. m.), while the rate of urinary excretion of ketamine was not significantly altered. Similarly, redistribution of intravenously administered ketamine (30 mg/kg i. v.) was slowed in the presence of halothane. In vitro hepatic microsomal metabolism of ketamine and its principle N-demethylated metabolite, metabolite I, was inhibited noncompetitively by halothane with inhibitor constants (Ki) for halothane estimated to be 1.56 and 1. 64 mM,respectively. The gas anesthetic also decreased the overall rate of in vivo metabolism of ketamine (30 mg/kg i. v.) in a concentration-dependent manner. Thus halothane anesthesia by decreasing uptake, distribution, redistribution and metabolism of intramuscularly administered ketamine produced significant prolongation of its pharmacologic action on the central nervous system. Our results imply that concomitant use of inhalational anesthetics may prolong pharmacologic actions of other agents via effects on distribution/redistribution processes as well as on metabolism.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1263110

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Pharmacokinetics of intravenous anaesthetics: implications for clinical use.

Authors:  M M Ghoneim; K Korttila
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

Review 2.  Pharmacokinetics in intravenous anaesthetic practice.

Authors:  P Duvaldestin
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

3.  Sex-dependent changes in ketamine-induced locomotor activity and ketamine pharmacokinetics in preweanling, adolescent, and adult rats.

Authors:  Sanders A McDougall; Ginny I Park; Goretti I Ramirez; Vanessa Gomez; Brittnee C Adame; Cynthia A Crawford
Journal:  Eur Neuropsychopharmacol       Date:  2019-04-10       Impact factor: 4.600

Review 4.  Clinical pharmacokinetics of the inhalational anaesthetics.

Authors:  O Dale; B R Brown
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

5.  The development of tolerance to ketamine in rats and the significance of hepatic metabolism.

Authors:  A Livingston; A E Waterman
Journal:  Br J Pharmacol       Date:  1978-09       Impact factor: 8.739

Review 6.  Pharmacokinetic drug interactions in anaesthetic practice.

Authors:  M Wood
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

7.  Pharmacokinetics of ketamine and two metabolites in the dog.

Authors:  J S Kaka; W L Hayton
Journal:  J Pharmacokinet Biopharm       Date:  1980-04

8.  Pharmacodynamic and pharmacokinetic interactions between ketamine and diazepam.

Authors:  J Idvall; K F Aronsen; P Stenberg; L Paalzow
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Comparison of behavioral effects of the NMDA receptor channel blockers memantine and ketamine in rats.

Authors:  Shawn E Kotermanski; Jon W Johnson; Edda Thiels
Journal:  Pharmacol Biochem Behav       Date:  2013-05-08       Impact factor: 3.533

10.  NMDA receptor hypofunction leads to generalized and persistent aberrant gamma oscillations independent of hyperlocomotion and the state of consciousness.

Authors:  Tahir Hakami; Nigel C Jones; Elena A Tolmacheva; Julien Gaudias; Joseph Chaumont; Michael Salzberg; Terence J O'Brien; Didier Pinault
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.